Cook's permanent vena cava filter:
This article was originally published in Clinica
Cook Medical has received US FDA 510(k) clearance to market its permanently implanted vena cava filter for capturing blood clots caused by medical conditions such as trauma and surgery before they can reach the lungs and cause a pulmonary embolism. The device, called Celect, was last year approved for permanent and retrieval indications in Canada, Australia and Europe. Trials are currently underway to study other aspects of the product, including its retrievability, said the Bloomington, Indiana firm. Celect employs a conical shape with a strut design that improves centering in the vessel and reduces in-growth, except at the desired end points.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.